- The FDA has signed off Xeris Pharmaceuticals Inc's XERS Investigational New Drug Application (IND) for its XeriSol levothyroxine (XP-8121) for hypothyroidism.
- Xeris will initiate a Phase 1 study to characterize Pharmacokinetics (PK) and evaluate the safety and tolerability of XP-8121 in healthy participants.
- Price Action: XERS shares are up 21.7% at $2.86 during the premarket session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefsHypothyroidism
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
